Inventiva S.A.

Paris Stock Exchange IVA.PA

Inventiva S.A. Operating Income Margin for the year ending December 31, 2023: -587.68%

Inventiva S.A. Operating Income Margin is -587.68% for the year ending December 31, 2023, a -25.33% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.
  • Inventiva S.A. Operating Income Margin for the year ending December 31, 2022 was -468.92%, a 62.26% change year over year.
  • Inventiva S.A. Operating Income Margin for the year ending December 31, 2021 was -1,242.58%, a 84.45% change year over year.
  • Inventiva S.A. Operating Income Margin for the year ending December 31, 2020 was -7,988.71%, a -1,744.32% change year over year.
  • Inventiva S.A. Operating Income Margin for the year ending December 31, 2019 was -433.15%, a 58.36% change year over year.
Key data
Date Operating Income Margin EBT Margin Net Income Margin EBITDA Margin
Market news
Loading...
SV Wall Street
Paris Stock Exchange: IVA.PA

Inventiva S.A.

CEO Mr. Frederic Cren
IPO Date Feb. 15, 2017
Location France
Headquarters 50 rue de Dijon
Employees 123
Sector Healthcare
Industries
Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Similar companies

ALCLS.PA

Cellectis S.A.

USD 1.61

2.90%

ARGX.BR

argenx SE

USD 667.09

1.81%

ABVX.PA

ABIVAX SA

USD 5.91

-2.66%

StockViz Staff

February 6, 2025

Any question? Send us an email